ViaCLYR™

Frequently Asked Questions (FAQs)

---

1. What is ViaCLYR™?

ViaCLYR™ is an FDA 510(k)-cleared medical device built upon the ClyraSept™ platform.

ViaCLYR™ is indicated for use by healthcare professionals for cleansing, irrigating, moistening, and debriding wounds. The solution assists in the removal of debris, necrotic tissue, dirt, and microorganisms from the wound bed through fluid movement across the surface.

ViaCLYR™ has demonstrated rapid neutralization of microorganisms in solution and in vitro persistence for up to 72 hours under controlled laboratory conditions.

---

2. What are the key components of ViaCLYR™?

ViaCLYR™ contains a proprietary Copper-Iodine Complex formulated in a saline-based solution with a dermal-friendly pH of approximately 5.0–5.2.

This balanced formulation supports wound bed preparation by:

- Neutralizing microorganisms upon contact (in solution)
- Assisting in the disruption of biofilm adherence
- Supporting removal of debris through mechanical irrigation

---

3. What are the FDA-cleared indications for use?

ViaCLYR ™ is intended for use by healthcare professionals for cleansing, irrigating, moistening, and debriding to remove wound debris from acute and chronic dermal lesions, including:

- First- and second-degree burns
- Stage I–IV pressure ulcers
- Diabetic ulcers
- Venous stasis ulcers
- Abrasions and minor skin irritations
- Post-surgical wounds
- Grafted and donor sites

ViaCLYR™ may also be used to moisten and lubricate absorbent wound dressings.

Refer to the Instructions for Use (IFU) for full details.

---

4. What are the key benefits of ViaCLYR™?

- Non-cytotoxic (validated through biocompatibility testing)
- Non-irritating
- Non-sensitizing
- No washout required following dwell application
- Compatible with standard wound care protocols

5. Can ViaCLYR™ be warmed prior to use?

Yes. Stability testing supports product integrity at:

- 40°C (104°F) for up to 6.7 months
- 55°C (131°F) for up to 1 month

This allows for use in hospital warming cabinets and in austere or high-temperature environments during transport or storage.

6. On what types of wounds can ViaCLYR™ be used?

ViaCLYR™ may be used on acute and chronic wounds within its FDA-cleared indications (see Question 3). It is appropriate for wounds of multiple etiologies where cleansing, irrigation, moistening, and debridement are indicated.

7. Can ViaCLYR™ help reduce contamination in the wound bed?

ViaCLYR assists in the removal of microorganisms through:

- Rapid neutralization in solution
- Mechanical irrigation
- Support of wound bed preparation protocols

Clinical case series and real-world evaluations have demonstrated significant reductions in bioburden following application, including use alongside fluorescence-based imaging technologies such as MolecuLight® and other assessment tools.

8. How should ViaCLYR™ be applied?

ViaCLYR™ may be applied:

- Pre- and post-debridement
- As a primary wound irrigant
- As a gauze-soaked dressing with dwell time (commonly ~10 minutes)
- In conjunction with secondary dressings

It may also be used alongside:

- Negative Pressure Wound Therapy (NPWT)
- Low-frequency ultrasound
- Hydrosurgical debridement (e.g., Versajet®)
- Skin substitutes and regenerative wound modalities

Always follow the Instructions for Use and institutional protocol.

9. How frequently can ViaCLYR™ be used?

ViaCLYR™ may be used as clinically indicated for wound bed preparation and irrigation. Because it has demonstrated biocompatibility and tissue-friendly properties, there are no defined over-utilization concerns within appropriate clinical use.

10. How does ViaCLYR ™work?

As an FDA-cleared medical device, ViaCLYR™ functions through:

© 2026 Clyra Medical Technologies, Inc.

- Neutralization of microorganisms in solution
- Mechanical removal of debris and contaminants through fluid movement

The Copper-Iodine Complex contributes to antimicrobial activity through contact-based interaction with microorganisms. Detailed biochemical mechanisms may be discussed by independent clinicians, but Clyra Medical Technologies promotes ViaCLYR consistent with its FDA-cleared device classification.

---

11. Are there any contraindications?

ViaCLYR™ should be used with caution in patients with Wilson's disease, a condition affecting copper metabolism. While systemic absorption is expected to be minimal when used as directed, clinicians should evaluate patient history appropriately.

Refer to the IFU for complete contraindications and precautions.

---

12. Can ViaCLYR™ be used on patients of all ages?

Yes. Clinical experience includes use across pediatric through geriatric populations within appropriate wound indications.

---

13. What is the pH of ViaCLYR™?

ViaCLYR™ has a pH of approximately 5.0–5.2, which aligns closely with normal dermal pH.

Chronic wounds often exhibit elevated (alkaline) pH levels that may contribute to microbial persistence. ViaCLYR™ supports restoration of a physiologic wound environment as part of comprehensive wound bed preparation.

---

14. Does ViaCLYR™ damage tissue?

No. ViaCLYR™ underwent rigorous biocompatibility testing as part of FDA clearance and demonstrated:

- Non-cytotoxicity
- Non-irritation
- Non-sensitization

These findings support its use in tissue-friendly wound management.

---

15. Does ViaCLYR™ damage fibroblasts?

Preclinical testing supports fibroblast viability in a pH-balanced wound environment when ViaCLYR is used as directed. Maintaining fibroblast activity is important for collagen production and granulation tissue formation.

---

16. Is ViaCLYR™ compatible with other wound care products?

Yes. ViaCLYR™ has demonstrated compatibility with:

- Autografts
- Allografts
- Skin substitutes
- Regenerative medicine products
- Standard advanced wound care technologies

It may be incorporated into comprehensive wound bed preparation protocols.

© 2026 Clyra Medical Technologies, Inc.